Nikki M Carroll1, Thomas Delate2, Alex Menter2, Mark C Hornbrook2, Lawrence Kushi2, Erin J Aiello Bowles2, Elizabeth T Loggers2, Debra P Ritzwoller2. 1. Kaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA Nikki.M.Carroll@kp.org. 2. Kaiser Permanente Colorado, Denver, CO; Kaiser Permanente Northwest, Portland, OR; Kaiser Permanente Northern California, Oakland, CA; The Group Health Research Institute; and Fred Hutchinson Cancer Research Center, Seattle, WA.
Abstract
PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. METHODS: Patients with stages IIIB-IV NSCLC age ≥ 21 years diagnosed between 2005 and 2010 who received first-line CP or CPB were identified at four health maintenance organizations (N = 1,109). Using patient and tumor characteristics and hospital and ambulatory encounters from automated data in the 180 days after chemotherapy initiation, the association between CP and CPB and toxicities and hospitalizations were evaluated with χ(2) tests and propensity score-adjusted regression models. RESULTS: Patients who received CPB were significantly younger and had significantly more bleeding, proteinuria, and GI perforation events (all P < .05). For these patients, the unadjusted odds ratio associated with the likelihood of having a hospitalization was 0.46 (95% CI, 0.32 to 0.67). As shown by multivariable and propensity score-adjusted models, patients who received CPB were less likely to have been hospitalized (odds ratio, 0.48; 95% CI, 0.32 to 0.71) and had fewer total hospitalizations (rate ratio, 0.62; 95% CI, 0.47 to 0.82) and hospital days (rate ratio, 0.53; 95% CI, 0.47 to 0.60) than patients who received CP. CONCLUSION: Consistent with earlier randomized clinical trials, significantly more toxicity events were identified in patients treated with CPB. However, both unadjusted and adjusted models showed that patients who received CPB were less likely than patients who received CP to experience a hospital-related event after the initiation of chemotherapy. Findings here confirm the need for adherence to clinical recommendations for judicious use of CPB, but provide reassurance regarding the relative risk for hospitalizations.
PURPOSE: Little is known regarding toxicities and hospitalizations in community-based settings for patients with advanced non-small-cell lung cancer (NSCLC) who received commonly prescribed carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) chemotherapy. METHODS:Patients with stages IIIB-IV NSCLC age ≥ 21 years diagnosed between 2005 and 2010 who received first-line CP or CPB were identified at four health maintenance organizations (N = 1,109). Using patient and tumor characteristics and hospital and ambulatory encounters from automated data in the 180 days after chemotherapy initiation, the association between CP and CPB and toxicities and hospitalizations were evaluated with χ(2) tests and propensity score-adjusted regression models. RESULTS:Patients who received CPB were significantly younger and had significantly more bleeding, proteinuria, and GI perforation events (all P < .05). For these patients, the unadjusted odds ratio associated with the likelihood of having a hospitalization was 0.46 (95% CI, 0.32 to 0.67). As shown by multivariable and propensity score-adjusted models, patients who received CPB were less likely to have been hospitalized (odds ratio, 0.48; 95% CI, 0.32 to 0.71) and had fewer total hospitalizations (rate ratio, 0.62; 95% CI, 0.47 to 0.82) and hospital days (rate ratio, 0.53; 95% CI, 0.47 to 0.60) than patients who received CP. CONCLUSION: Consistent with earlier randomized clinical trials, significantly more toxicity events were identified in patients treated with CPB. However, both unadjusted and adjusted models showed that patients who received CPB were less likely than patients who received CP to experience a hospital-related event after the initiation of chemotherapy. Findings here confirm the need for adherence to clinical recommendations for judicious use of CPB, but provide reassurance regarding the relative risk for hospitalizations.
Authors: Julie R Brahmer; Suzanne E Dahlberg; Robert J Gray; Joan H Schiller; Michael C Perry; Alan Sandler; David H Johnson Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: B J Paessens; C von Schilling; K Berger; M Shlaen; C Müller-Thomas; R Bernard; C Peschel; A Ihbe-Heffinger Journal: Ann Oncol Date: 2011-02-22 Impact factor: 32.976
Authors: Mark C Hornbrook; Gene Hart; Jennifer L Ellis; Donald J Bachman; Gary Ansell; Sarah M Greene; Edward H Wagner; Roy Pardee; Mark M Schmidt; Ann Geiger; Amy L Butani; Terry Field; Hassan Fouayzi; Irina Miroshnik; Liyan Liu; Robert Diseker; Karen Wells; Rick Krajenta; Lois Lamerato; Christine Neslund Dudas Journal: J Natl Cancer Inst Monogr Date: 2005
Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Supriya G Mohile; Molly Hardt; William Tew; Cynthia Owusu; Heidi Klepin; Cary Gross; Ajeet Gajra; Stuart M Lichtman; Tao Feng; Kayo Togawa; Rupal Ramani; Vani Katheria; Kurt Hansen; Arti Hurria Journal: Oncologist Date: 2013-04-10
Authors: Ruth P Norris; Rosie Dew; Linda Sharp; Alastair Greystoke; Stephen Rice; Kristina Johnell; Adam Todd Journal: BMC Med Date: 2020-10-23 Impact factor: 8.775